The biopharmaceutical company Curevac stops development of a corona vaccine.
(Photo: imago images / ULMER press picture agency)
Dusseldorf The realignment of the Tübingen company Curevac is not well received on the stock market. After this news, the shares slipped by more than 15 percent and were quoted at around 32 euros on Tuesday lunchtime.
The biotech company is giving up its Covid vaccine and instead wants to focus more on the successor product and the alliance with Glaxo-Smith-Kline. This will de facto make Curevac a biotech company that is still in the early stages of its development.
The example of Curevac shares shows how risky vaccine manufacturer papers are. After the successful IPO in August of last year, the price doubled very quickly. On December 9, 2020, the paper reached its record high of 120.82 euros. After that, things went downhill significantly.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further